单位：[1]Erasmus University Medical Center[2]Gastroenterology and Hepatology, Erasmus University Medical Center[3]Institute of Digestive Disease, Department of Medicine and Therapeutics, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong[4]Nkc Institute of Gastroenterology and Hepatology[5]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[6]Universitätsklinikum Frankfurt[7]Liver Research Unit, Chang Gung Memorial Hospital[8]Toronto Centre for Liver Disease, University Health Network[9]University of Toronto[10]Roche Products Limited, Roche Products Ltd[11]Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[12]Hospital Universitari Vall d’Hebron, Barcelona, Spain[13]Gastroenterology and Hepatology, Erasmus Medical Centre
Sonneveld Milan J.,Brouwer Willem Pieter,Chan Henry Lik Yuen,et al.Optimizing the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the Sonic-B Study[J].HEPATOLOGY.2018,68:1180A-1181A.
APA：
Sonneveld, Milan J.,Brouwer, Willem Pieter,Chan, Henry Lik Yuen,Piratvisuth, Teerha,Jia, Jidong...&Janssen, Harry L. A..(2018).Optimizing the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the Sonic-B Study.HEPATOLOGY,68,
MLA：
Sonneveld, Milan J.,et al."Optimizing the Use of APRI and FIB-4 to Rule out Cirrhosis in Patients with Chronic Hepatitis B: Results from the Sonic-B Study".HEPATOLOGY 68.(2018):1180A-1181A
医学